G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee
12 févr. 2024 16h05 HE
|
G1 Therapeutics
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent DMC
G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference
08 janv. 2024 06h45 HE
|
G1 Therapeutics
G1 Therapeutics provides Corporate and Clinical Update at the 42md Annual J.P. Morgan healthcare conference.
G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
03 janv. 2024 09h00 HE
|
G1 Therapeutics
G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 janv. 2024 16h51 HE
|
G1 Therapeutics
January 2024 Inducement Grants
G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy
05 déc. 2023 09h26 HE
|
G1 Therapeutics
G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 déc. 2023 16h27 HE
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Dec. 01, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options...
G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer Symposium
29 nov. 2023 20h37 HE
|
G1 Therapeutics
New data at the 2023 SABCS explore the long-term impact of trilaciclib on survival outcomes in patients with metastatic TNBC
G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights
01 nov. 2023 06h30 HE
|
G1 Therapeutics
G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights
Real World Data Indicate That Trilaciclib Reduces Hospitalizations and Myelosuppressive Events and May Improve Survival in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
27 oct. 2023 07h00 HE
|
G1 Therapeutics
Trilaciclib Reduces Hospitalizations and Myelosuppressive Events in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC) and May Improve Survival
G1 Therapeutics’ COSELA® (trilaciclib) Recommended in Updated Small Cell Lung Cancer Guidelines from the American Society of Clinical Oncology (ASCO)
18 oct. 2023 08h00 HE
|
G1 Therapeutics
G1 Therapeutic's COSELA (trilaciclib) included in ASCO's updated SCLC treatment guidelines